Chiara Robba1, Susanna Bacigaluppi2, Nicola Bragazzi3, Andrea Lavinio4, Mark Gurnell5, Federico Bilotta6, David K Menon4. 1. Neurosciences Critical Care Unit, Addenbrooke's Hospital, Cambridge University, Cambridge University Hospitals Trust, Box 1, Hills Road, Cambridge, CB2 0QQ, UK. kiarobba@gmail.com. 2. Department of Neurosurgery, Galliera Hospital, Mura delle Cappuccine 14, 16128, Genoa, Italy. 3. Department of Health Sciences (DISSAL), University of Genoa, Largo Rosanna Benzi, 15, 16100, Genoa, Italy. 4. Neurosciences Critical Care Unit, Addenbrooke's Hospital, Cambridge University, Cambridge University Hospitals Trust, Box 1, Hills Road, Cambridge, CB2 0QQ, UK. 5. Department of Medicine, Addenbrooke's Hospital, Cambridge University, Cambridge University Hospitals Trust, Box 1, Hills Road, Cambridge, CB2 0QQ, UK. 6. Department of Anesthesiology, University of Rome "La Sapienza", Piazzale Aldo Moro 5, 00185, Rome, Italy.
Abstract
PURPOSE: Pituitary dysfunction is reported to be a common complication following aneurysmal subarachnoid hemorrhage (aSAH). The aim of this meta-analysis is to analyze the literature on clinical prevalence, risk factors and outcome impact of pituitary dysfunction after aSAH, and to assess the possible need for pituitary screening in aSAH patients. METHODS: We performed a systematic review with meta-analysis based on a comprehensive search of four databases (PubMed/MEDLINE, ISI/Web of Science, Scopus and Google Scholar). RESULTS: A total of 20 papers met criteria for inclusion. The prevalence of pituitary dysfunction in the acute phase (within the first 6 months after aSAH) was 49.30 % (95 % CI 41.6-56.9), decreasing in the chronic phase (after 6 months from aSAH) to 25.6 % (95 % CI 18.0-35.1). Abnormalities in basal hormonal levels were more frequent when compared to induction tests, and the prevalence of a single pituitary hormone dysregulation was more frequent than multiple pituitary hormone dysregulation. Increasing age was associated with a lower prevalence of endocrine dysfunction in the acute phase, and surgical treatment of the aneurysm (clipping) was related to a higher prevalence of single hormone dysfunction. The prevalence of pituitary dysfunction did not correlate with the outcome of the patient. CONCLUSIONS: Neuroendocrine dysfunction is common after aSAH, but these abnormalities have not been shown to consistently impact outcome in the data available. There is a need for well-designed prospective studies to more precisely assess the incidence, clinical course, and outcome impact of pituitary dysfunction after aSAH.
PURPOSE:Pituitary dysfunction is reported to be a common complication following aneurysmal subarachnoid hemorrhage (aSAH). The aim of this meta-analysis is to analyze the literature on clinical prevalence, risk factors and outcome impact of pituitary dysfunction after aSAH, and to assess the possible need for pituitary screening in aSAH patients. METHODS: We performed a systematic review with meta-analysis based on a comprehensive search of four databases (PubMed/MEDLINE, ISI/Web of Science, Scopus and Google Scholar). RESULTS: A total of 20 papers met criteria for inclusion. The prevalence of pituitary dysfunction in the acute phase (within the first 6 months after aSAH) was 49.30 % (95 % CI 41.6-56.9), decreasing in the chronic phase (after 6 months from aSAH) to 25.6 % (95 % CI 18.0-35.1). Abnormalities in basal hormonal levels were more frequent when compared to induction tests, and the prevalence of a single pituitary hormone dysregulation was more frequent than multiple pituitary hormone dysregulation. Increasing age was associated with a lower prevalence of endocrine dysfunction in the acute phase, and surgical treatment of the aneurysm (clipping) was related to a higher prevalence of single hormone dysfunction. The prevalence of pituitary dysfunction did not correlate with the outcome of the patient. CONCLUSIONS:Neuroendocrine dysfunction is common after aSAH, but these abnormalities have not been shown to consistently impact outcome in the data available. There is a need for well-designed prospective studies to more precisely assess the incidence, clinical course, and outcome impact of pituitary dysfunction after aSAH.
Authors: Z Karaca; F Tanriverdi; A T Dagli; A Selcuklu; F F Casanueva; K Unluhizarci; F Kelestimur Journal: Pituitary Date: 2013-03 Impact factor: 4.107
Authors: Mellanie V Springer; J Michael Schmidt; Katja E Wartenberg; Jennifer A Frontera; Neeraj Badjatia; Stephan A Mayer Journal: Neurosurgery Date: 2009-12 Impact factor: 4.654
Authors: Lakshmi Srinivasan; Brian Roberts; Tamara Bushnik; Jeffrey Englander; David A Spain; Gary K Steinberg; Li Ren; M Elizabeth Sandel; Zahraa Al-Lawati; Jeffrey Teraoka; Andrew R Hoffman; Laurence Katznelson Journal: Brain Inj Date: 2009-07 Impact factor: 2.311
Authors: Stepani Bendel; Timo Koivisto; Esko Ruokonen; Jaakko Rinne; Jarkko Romppanen; Ilkka Vauhkonen; Vesa Kiviniemi; Ari Uusaro Journal: Crit Care Date: 2008-10-13 Impact factor: 9.097